Arash Matian, DO
Family Medicine · Sherman Oaks, CANPI 1558300582
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $950 of the $1,488 with a category attached, or 63.9%. Alnylam Pharmaceuticals Inc. accounts for 88.0% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $1,310 and has fallen 97.9% since, to $27 in 2025.
Across 22 payments — averaging $67.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$44
- Lilly USA, LLC$27
- Pfizer$27
- Medtronic$20
- Otsuka America Pharmaceutical, Inc.$18
- plus $42 from 3 others
Across 250 payments — averaging $4919.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$356K
- Eli Lilly$340K
- Alnylam Pharmaceuticals Inc.$270K
- Endo Pharmaceuticals Inc.$70K
- GSK$60K
- Organon$48K
- plus $85K from 5 others
What the payments were for
- Travel & lodging$95064%
- Food & beverage$53836%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 10 | $1,310 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $44 |
| Lilly USA, LLC | 2 | $27 |
| Pfizer | 1 | $27 |
| Medtronic | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Vertiflex, Inc. | 1 | $12 |
How this compares
$1,488 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 15 | $10,414 |
| Tamsulosin Hcl | 32 | $900 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 14 | $887 |
| Rosuvastatin Calcium | 35 | $747 |
| Metformin Hcl | 60 | $612 |
| Lisinopril | 48 | $433 |
| Trazodone Hcl | 37 | $431 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 25 | $400 |
| Atorvastatin Calcium | 80 | $380 |
| Finasteride | 22 | $374 |
| Gabapentin | 41 | $367 |
| Metoprolol Succinate | 23 | $353 |
| Pantoprazole Sodium | 29 | $325 |
| Amlodipine Besylate | 64 | $301 |
| Omeprazole | 28 | $268 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Sherman Oaks
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.